Double PET scan may unlock secrets of gut tumors
NCT ID NCT04804371
First seen Apr 06, 2026 · Last updated Jun 19, 2026 · Updated 10 times
Summary
This pilot study is testing whether combining two different PET scans can give doctors a clearer picture of neuroendocrine tumors (NETs) in the gut. The scans measure how tumors take up different tracers, which may reveal whether a tumor is slow-growing or aggressive. The goal is to see if this information helps doctors choose the best treatment for each patient. The study involves 40 adults with well-differentiated G2-G3 GEP-NETs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
F18-FDG (a radioactive tracer for PET scans)
What this could lead to
If successful, this could help doctors choose better treatments for patients with intermediate-grade neuroendocrine tumors by identifying which tumors are more aggressive.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply to everyone. It is designed to gather information, not to test a new treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.